Novartis To Sell Flu Vaccine Adjuvant To Korea's Green Cross
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean vaccine maker Green Cross recently signed a deal with Novartis to buy the latter's adjuvanted A/H1N1 vaccine MF59 to expand Green Cross' A/H1N1 vaccine production volume